Today: 20 May 2026
Browse Category

NASDAQ:NICE 29 July 2025 - 6 May 2026

NICE Stock Tumbles After an Earnings Beat. The Guidance Is Why

NICE Stock Tumbles After an Earnings Beat. The Guidance Is Why

NICE Ltd. shares fell 22.9% to $96.35 after the company forecast second-quarter revenue below Wall Street estimates. First-quarter revenue and earnings beat expectations, with cloud revenue up 14.6% and AI annual recurring revenue up 66%. GAAP net income dropped to $46.8 million from $129.3 million a year earlier. NICE cited timing effects from large customer renewals as a factor in the outlook.
NICE stock price rises again premarket as $600 million buyback and AI metrics grab attention

NICE stock price rises again premarket as $600 million buyback and AI metrics grab attention

NICE Ltd shares rose 1.8% to $113.59 in premarket trading after reporting fourth-quarter profit of $150.6 million, up from $99.5 million a year earlier. Cloud revenue grew 14% in Q4, with AI annual recurring revenue up 66% to $328 million. The company forecast 2026 revenue of $3.17–$3.19 billion and announced a new $600 million share repurchase program pending its 2025 audited report.
NICE Ltd (NICE) Stock Hits Lowest Level Since 2019 as Wall Street Slashes Price Targets After AI-First Pivot

NICE Ltd (NICE) Stock Hits Lowest Level Since 2019 as Wall Street Slashes Price Targets After AI-First Pivot

NICE Ltd. shares plunged over 15% Tuesday to their lowest since 2019 after the company announced a $160 million increase in AI spending and warned of lower 2026 margins at its Capital Markets Day. The sell-off followed strong Q3 results but triggered fresh analyst downgrades and erased recent gains, with NICE’s valuation now down more than 30% year-to-date.
NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance

NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance

NICE Ltd. reported Q3 2025 revenue of $732 million, up 6% and above analyst expectations, with cloud revenue rising 13% to $562.9 million. GAAP net income reached $144.9 million, up 20% from a year earlier. The company raised its full-year non-GAAP revenue outlook but trimmed EPS guidance. Shares rose 6–9% in pre-market trading after results.
WIZ.AI vs Cognigy vs Kore.ai – The Ultimate 2025 Conversational AI Platform Showdown

WIZ.AI vs Cognigy vs Kore.ai – The Ultimate 2025 Conversational AI Platform Showdown

WIZ.AI, based in Singapore, launched TalkGPT in 2023 and reported 300 clients across 17 countries by 2024. In June 2025, WIZ.AI partnered with Agora for real-time voice calls. Cognigy was acquired by NICE for $955 million in July 2025 after being named a Gartner Leader and powering automation for Lufthansa and DHL. Kore.ai raised $150 million in 2024 with NVIDIA investment and released XO Platform v11 in April 2024.
AI Revolution Unleashed: Breakthroughs, Big Tech Gambits & Ethical Firestorms (Late July 2025)

AI Revolution Unleashed: Breakthroughs, Big Tech Gambits & Ethical Firestorms (Late July 2025)

The White House released the AI Action Plan on July 23, outlining over 90 federal initiatives. Senate Democrats on July 29 warned that resuming Nvidia AI chip sales to China could threaten U.S. security. At WAIC in Shanghai, Premier Li Qiang proposed an international AI body, and Huawei unveiled CloudMatrix 384, claiming it outperforms Nvidia’s NVL72. Amazon announced the acquisition of Bee, a $50 AI wearable startup.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Go toTop